Surrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Purchases 15,223 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 15,223 shares of the stock in a transaction on Monday, March 23rd. The shares were bought at an average price of $24.90 per share, for a total transaction of $379,052.70. Following the acquisition, the insider owned 683,225 shares of the company’s stock, valued at approximately $17,012,302.50. The trade was a 2.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Tuesday, March 24th, Tcg Crossover Gp Ii, Llc acquired 106,658 shares of Surrozen stock. The stock was purchased at an average price of $24.69 per share, with a total value of $2,633,386.02.
• On Monday, March 16th, Tcg Crossover Gp Ii, Llc acquired 1,190 shares of Surrozen stock. The stock was purchased at an average price of $24.99 per share, with a total value of $29,738.10.
• On Friday, March 13th, Tcg Crossover Gp Ii, Llc acquired 35,433 shares of Surrozen stock. The shares were purchased at an average cost of $24.88 per share, with a total value of $881,573.04.
• On Thursday, March 12th, Tcg Crossover Gp Ii, Llc bought 12,374 shares of Surrozen stock. The stock was purchased at an average price of $24.99 per share, for a total transaction of $309,226.26.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc bought 1,093 shares of Surrozen stock. The stock was purchased at an average price of $23.86 per share, for a total transaction of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc bought 17,763 shares of Surrozen stock. The shares were purchased at an average cost of $23.57 per share, with a total value of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc bought 4,355 shares of Surrozen stock. The shares were purchased at an average cost of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc purchased 731 shares of Surrozen stock. The shares were purchased at an average price of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc purchased 4,271 shares of Surrozen stock. The shares were purchased at an average price of $21.39 per share, with a total value of $91,356.69.

Surrozen Trading Up 4.6%

Shares of NASDAQ:SRZN traded up $1.14 during midday trading on Wednesday, hitting $26.14. The company’s stock had a trading volume of 47,046 shares, compared to its average volume of 89,411. The stock’s 50 day simple moving average is $24.34 and its 200 day simple moving average is $18.81. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $29.59.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($7.59) earnings per share for the quarter, missing the consensus estimate of ($1.29) by ($6.30). Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%.The business had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.66 million. Equities research analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Wall Street Zen upgraded Surrozen to a “sell” rating in a report on Friday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price (up from $32.00) on shares of Surrozen in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $40.00 target price on shares of Surrozen in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $38.00.

Hedge Funds Weigh In On Surrozen

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Surrozen during the 4th quarter worth approximately $99,000. Citadel Advisors LLC increased its position in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after purchasing an additional 3,424 shares during the period. Marshall Wace LLP acquired a new position in shares of Surrozen in the fourth quarter valued at $247,000. Finally, Geode Capital Management LLC raised its stake in shares of Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.